Seeking Alpha

Puma Biotechnology (PBYI +5.6%) moves up today after announcing the initiation of Phase III...

Puma Biotechnology (PBYI +5.6%) moves up today after announcing the initiation of Phase III clinical trials of its lead drug candidate neratinib, a treatment for HER2-positive metastatic breast cancer. The trial will be conducted at approximately 150 sites in North America, Europe and Asia-Pacific, and if successful willl be used to submit an accelerated approval application with the FDA.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|